KMT2A and acute myeloid leukemia: Novel, more potent and stable MENIN PPIs with increased selectivity for KMT2A fusions have been presented at ASH 2018 with potent anti-leukemic activity in patient-derived xenotransplant (PDX) models of AML (121).